Nishant’s practice focuses on corporate and securities law matters. Nishant routinely advises issuers, investors, and investment banking firms on a variety of transactions, with a focus on initial public offerings, follow-on offerings, private investments in public equity (PIPEs), registered direct offerings, SPACs, and mergers and acquisitions. Nishant also provides counsel to public and private companies on corporate governance, SEC reporting and disclosure requirements, compliance matters and stock exchange requirements. Nishant advises clients in a wide range of industries, including health care, life sciences, medical device, technology, and energy and sustainability.
Experience
Select Initial Public Offering Representations
- ArriVent BioPharma, Inc. in its $200 million initial public offering
- Viela Bio, Inc. in its $172.5 million initial public offering
- Cowen and Company as lead underwriter in Praxis Precision Medicines, Inc.’s $218 million initial public offering
- G1 Therapeutics, Inc. in its $121 million initial public offering
- Sera Prognostics, Inc. in its $80 million initial public offering
Select Follow-on Offering and Alternate Transaction Representations
- Viela Bio, Inc. in its $170 million follow-on offering
- Goldman Sachs as lead underwriter in Fulcrum Therapeutics, Inc.’s $143 million follow-on offering and $75 million follow-on offering
- Leerink Partners as lead underwriter in MoonLake Immunotherapeutics' $460 million follow-on offering
- Piper Sandler as lead underwriter in Praxis Precision Medicines, Inc.’s $172 million follow-on offering
- Aspen Aerogels, Inc. in its $275 million follow-on offering and its $75 million registered direct offering
- Aspen Aerogels, Inc. in a $100 million Convertible Note PIPE with an affiliate of Koch Strategic Platforms, LLC
- Synlogic, Inc. in multiple follow-on offerings raising aggregate proceeds of $180 million
- Aspen Aerogels, Inc. in $125 million common stock PIPEs with an affiliate of Koch Strategic Platforms, LLC
- J.P. Morgan as lead underwriter in Acceleron Pharma Inc.’s $230 million follow-on offering
- Cowen and Company as lead underwriter in Rocket Pharmaceuticals, Inc.’s $85 million follow-on offering
- Truist Securities as sole placement agent in Verastem Oncology, Inc.’s $60 million Series B Convertible Preferred Stock PIPE
- William Blair & Company as sole placement agent in Vapotherm, Inc.’s $23 million PIPE
- Leerink Partners as lead underwriter in ArQule, Inc.’s $65 million follow-on offering
Select Mergers and Acquisitions Representations
- Viela Bio, Inc. in its $3.05 billion sale to Horizon Therapeutics, Inc.
- NET Power, Inc. in a business combination / de-SPAC to create a combined company valued at $1.5 billion
- Elicio Therapeutics, Inc. in its reverse merger with Angion BioMedica Corp.
- Molecular Templates, Inc. in its reverse merger with Threshold Pharmaceuticals, Inc.
- Synta Pharmaceuticals Corp. in its reverse merger with Madrigal Pharmaceuticals, Inc.
- Seventh Generation, Inc. in its sale to Unilever
- Presence Learning, Inc. in its acquisition of Global Therapy and a concurrent majority investment from Spectrum Equity, and The Rise Fund, TPG’s multi-sector global impact investment strategy
News & Press
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Twenty-nine Mintz Attorneys Named to 2023 New York Metro Super Lawyers List
September 22, 2023
NEW YORK – Mintz is pleased to announce that 18 attorneys have been named New York Metro Super Lawyers and 11 attorneys have been named New York Metro Rising Stars by Super Lawyers for 2023.
Mintz represented G1 Therapeutics, Inc. in its initial public offering of 7,781,564 shares of common stock. G1 Therapeutics is a clinical-stage biopharmaceutical company.
Mintz Represents Seventh Generation, Inc. in Sale to Unilever
October 27, 2016
Mintz attorneys represented Seventh Generation, Inc. in its recent sale to Unilever. Based in Vermont, Seventh Generation is a pioneer in corporate responsibility and sustainable product innovations, including plant-based detergents and household cleaners.
Recognition & Awards
- New York Super Lawyers Rising Stars: Corporate (2023)
Recent Insights
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
NEW YORK – Mintz is pleased to announce that 18 attorneys have been named New York Metro Super Lawyers and 11 attorneys have been named New York Metro Rising Stars by Super Lawyers for 2023.
